Bone Graft
-
Biologics
Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft
The ASPIRE study is intended to evaluate the use of P-15L Bone Graft in transforaminal lumbar interbody fusion surgery in…
Read More » -
Spine
Orthofix Announces US Launch and First Patient Implants with New fiberFUSE Strip – An Advanced Fiber Bone-Graft Solution Containing Cancellous Bone
July 28, 2021 LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus,…
Read More » -
Biologics
Paragon 28® Inc., Expands its Novel Biologics Portfolio with Addition of Three Families of DBM
Introducing BEAST™ Injectable, BEAST PLUS™, and BEAST™ Osteobiologic Sponge (BOB™) for bone grafting applications in the foot and ankle. ENGLWOOD,…
Read More » -
Biologics
Biogennix’s Agilon Moldable Bone Graft Solution Achieves Sales Surge Amid Adoption by Foot and Ankle Surgeons
IRVINE, Calif. — May 19, 2021 — Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft…
Read More » -
Biologics
Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
– P-15L Bone Graft is currently being studied in the Company’s ASPIRE IDE clinical trial – WESTMINSTER, Colo., April 29, 2021 /PRNewswire/…
Read More » -
Biologics
Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation
DEERFIELD, Ill., Jan. 12, 2021 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc. (Nasdaq: SRGA), a global pure-play spine company focused on…
Read More » -
Biologics
SeaSpine Announces Publication of Results from a Cellular Bone Graft Study in The Journal of Bone and Joint Surgery (JBJS)
CARLSBAD, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on…
Read More » -
Biologics
Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK
October 7, 2020 LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus,…
Read More » -
Biologics
Cerapedics Announces Canadian Approval of its next-generation bone graft
Canada will be the first commercial market to launch i-FACTOR®+ Matrix WESTMINSTER, Colo., September 15, 2020 — Cerapedics, a private…
Read More » -
Biologics
SurGenTec® Announces FDA Clearance for OsteoFlo® NanoPutty® (Quadphasic Synthetic Bone Graft)
August 26, 2020 BOCA RATON, Fla.–(BUSINESS WIRE)–SurGenTec, a privately held spine and orthopedic technology company, announced today that it has…
Read More » -
Biologics
Cerapedics Announces FDA approval of an IDE supplement
WESTMINSTER, Colo., July 22, 2020 — Cerapedics, a private ortho-biologics company, today announced the U.S. Food and Drug Administration (FDA)…
Read More » -
Regulatory
Medtronic pulls Infuse bone graft from Australia
June 30, 2020 / Alan Condon Medtronic has withdrawn its Infuse Bone Graft/LT-Cage Lumbar Tapered Fusion device from the Australian…
Read More » -
Biologics
SIRAKOSS Receives U.S. FDA 510(k) Clearance for Osteo3 ZP Putty to Catalyse Rapid and Complete Bone Regeneration
Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes, announced today that it has received…
Read More » -
Biologics
Cerapedics Announces Results from Clinical Trial of i-FACTOR® Peptide Enhanced Bone Graft in Lumbar Fusion Surgery
WESTMINSTER, Colo., May 19, 2020 /PRNewswire/ — Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide…
Read More » -
Biologics
Randomized Controlled Trial Results Published in ‘Spine’ Demonstrate Efficacy of NuVasive Attrax® Putty in Posterolateral Lumbar Fusion
– Attrax Putty is now the first and only ceramic bone graft substitute supported by Level I evidence to demonstrate…
Read More »